Accessing Gene Expression in Treatment-Resistant Schizophrenia

• Published in: Molecular neurobiology 2018-08, Vol.55 (8), p.7000-7008
• Main Authors: Moretti, Patricia N., Ota, Vanessa K., Gouvea, Eduardo S., Pedrini, Mariana, Santoro, Marcos L., Talarico, Fernanda, Spindola, Leticia M., Carvalho, Carolina Muniz, Noto, Cristiano, Xavier, Gabriela, Brietzke, Elisa, Gadelha, Ary, Bressan, Rodrigo, Mari, Jair, Belangero, Sintia
• Format: Article
• Language: English
• Subjects: Adult; AKT1 protein; Antipsychotics; Biodegradation; Biomarkers; Biomedical and Life Sciences; Biomedicine; Cell Biology; Cellular stress response; Clinical trials; Drug Resistance - genetics; Environmental factors; Female; Gene expression; Gene Expression Regulation; Gene polymorphism; Genotypes; Humans; Information processing; Male; Mental disorders; miRNA; Myelination; Neurobiology; Neurology; Neuroplasticity; Neurosciences; Neurotransmission; Neurotransmitters; Peripheral blood; Quantitative trait loci; Quantitative Trait Loci - genetics; RNA, Messenger - genetics; RNA, Messenger - metabolism; Schizophrenia; Schizophrenia - drug therapy; Schizophrenia - genetics; Single-nucleotide polymorphism; Treatment resistance
• ISSN: 0893-7648; 1559-1182
• DOI: 10.1007/s12035-018-0876-4

Schizophrenia (SCZ) is a mental disorder arising from a complex interaction of genetic and environmental factors. It has been suggested that treatment-resistant schizophrenia (TRS) is a distinct, more severe, and homogenous subgroup of schizophrenia that could present specific biological markers. Our aim was to characterize expression of target genes in blood of TRS patients compared with non-TRS (NTRS) patients and healthy controls (HC). TRS has been defined using failure to respond to two previous antipsychotic trials. We hypothesized that genes involved in neurodevelopment, myelination, neuroplasticity, neurotransmission, and miRNA processing could be involved in treatment resistance; then, we investigated 13 genes related to those processes in 256 subjects, being 94 healthy controls and 162 schizophrenia patients treated with antipsychotics. Of those, 78 were TRS patients and 84 were NTRS patients. Peripheral blood samples were collected from all subjects and RNA was isolated. Gene expression analysis was performed using the TaqMan low-density array (TLDA) technology. To verify the influence of expression quantitative trait loci (eQTLs), we evaluated single-nucleotide polymorphism (SNP) of all genes using data from GTEx Project. SNP genotypes were obtained from HumanOmniExpress BeadChip. We did not detect gene expression differences between TRS and NTRS subjects, indicating candidate genes specific to treatment resistance. We detected an upregulation of CNR1 and UFD1L gene expression in patients (TRS and NTRS groups) when compared to controls, that may be associated with the release of neurotransmitters, which can influence neuronal plasticity, or with a stress response-activating protein degradation. DICER1 and AKT1 expression increased slightly across the groups and could differentiate only the extreme opposite groups, HC and TRS. Both genes act in heterogeneous pathways, such as cell signaling and miRNA processing, and seem to have an increased demand in the TRS group. We did not detect any eQTLs in our sample that could explain differences in mRNA levels, suggesting a possible regulation by other mechanism, not driven by genotypes. Our data strengthen the importance of several biological pathways involved in the schizophrenia refractoriness and severity, adding knowledge to develop more effective treatments in the future.